More than half of Covid-19 patients discharged from hospitals still experienced symptoms of breathlessness, fatigue, anxiety and depression for two to three months after their initial infection, according to the findings of a small UK study.

The U.S. Food and Drug Administration approved Nucala (mepolizumab) for adults and children aged 12 years and older with hypereosinophilic syndrome (HES) for six months or longer without another identifiable non-blood related cause of the disease.

A study published in the scientific journal Nature explains why certain kinds of cancer cells often spread to the lymph nodes before various organs within the body.

The U.S. Food and Drug Administration approved Alexion Pharmaceuticals Inc.’s Ultomiris for the treatment of atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy for adult and pediatric patients.

Deep Genomics’ proprietary artificial intelligence-based drug discovery platform identified a novel treatment target and corresponding drug candidate for the rare and potentially life-threatening genetic disorder Wilson disease.

A new discovery at the Feinstein Institutes for Medical Research could have implications in the way diabetes is treated in the future.

A federal grand jury recently filed criminal charges against several developers for fraud involving a Vermont biotech company.

GW Pharmaceuticals Plc said the company’s drug Epidiolex was successful in treating seizures in patients with a rare form of childhood epilepsy called tuberous sclerosis complex during a late-stage trial.

There has been significant progress in so-called bioprinting – using a type of 3D printing to manufacture biological tissues. But an actual organ had not been accomplished – until now.

Pfizer acquired a 15 percent stake in Vivet Therapeutics as well as an exclusive option to fully acquire the business, a deal that will give the New York-based pharma giant access to the French company’s experimental gene therapy for a rare genetic disorder.